نتایج جستجو برای: remission maintenance therapy

تعداد نتایج: 804901  

Journal: :journal of family and reproductive health 0
hajieh borna mostafa khomeini hospital, shahed university of medicine, tehran, iran sedigheh borna department of perinatology, medical sciences/ university of tehran, tehran, iran soghra khazardoust department of perinatology, medical sciences/ university of tehran, tehran, iran sedigheh hantoushzadeh department of perinatology, medical sciences/ university of tehran, tehran, iran noshin sahabi obstetrician and gynecologist

objective : the study evaluated the efficacy and safety of vaginal rogesterone on prevention of recurrent preterm labor. materials and methods: total number of 70 patients with preterm labor treated with intravenous magnesium sulfate in perinatology department of valiasr hospital entered to a randomized clinical trial. treatment group after inhibition of preterm labor with magnesium sulfate rec...

Journal: :The Netherlands journal of medicine 2012
M P Connolly C Boersma B Oldenburg

BACKGROUND In this study we investigate the costs and benefits of topical mesalazine combined with oral mesalazine therapy for active ulcerative colitis (UC), and once daily (OD ) mesalazine 2 grams versus twice daily (BID ) for maintaining UC remission. METHODS Two decision analytic models were constructed to evaluate treatment costs and quality-adjusted life years (QALYs) associated with me...

2015
Vivian W. Huang Connie Prosser Karen I. Kroeker Haili Wang Carol Shalapay Neil Dhami Darryl K. Fedorak Brendan Halloran Levinus A. Dieleman Karen J. Goodman Richard N. Fedorak

BACKGROUND Infliximab is an effective therapy for inflammatory bowel disease (IBD). However, more than 50% of patients lose response. Empiric dose intensification is not effective for all patients because not all patients have objective disease activity or subtherapeutic drug level. The aim was to determine how an objective marker of disease activity or therapeutic drug monitoring affects clini...

Journal: :Annals of oncology : official journal of the European Society for Medical Oncology 2006
A D Zelenetz

Although response rates are increased, the addition of rituximab to induction chemotherapy has not yet been proven to extend the progression-free and overall survival benefits of chemotherapy alone. In first remission, high-dose therapy plus stem cell rescue improves time to treatment failure and progression-free survival when compared with maintenance interferon alpha. However, relapse rate do...

2017
Dario Roccatello Savino Sciascia Daniela Rossi Mirella Alpa Carla Naretto Massimo Radin Roberta Fenoglio Simone Baldovino Elisa Menegatti

BACKGROUND ANCA associated vasculitides (AAV) often present with a chronic relapsing course. Relapse leads to increased immunosuppressive exposure and consequent toxicity. While two randomized controlled trials have shown rituximab (RTX) to be the most effective induction treatment in patients with relapsing disease, the optimal treatment duration and RTX dose remain debated. Whether to adminis...

Journal: :Postgraduate medical journal 1981
S J Proctor R Finney W Walker R B Thompson

Seventeen adult patients with previously untreated acute lymphoblastic leukaemia (ALL) were entered into a schedule of chemotherapy in which 3 combinations, each of 4 drugs, were administered in a predetermined cyclical rotation in combination with cranial irradiation and intrathecal injections of methotrexate. Of the 17 patients, 16 completed induction therapy and 15 (94%) entered remission. T...

2014
Hyun Il Seo Dong Il Park Tae Oh Kim You Sun Kim Suck-Ho Lee Ji Won Kim Jae Hak Kim Jeong Eun Shin

BACKGROUND/AIMS Infliximab was introduced recently as a rescue therapy for ulcerative colitis (UC) patients refractory to conventional treatments such as therapy with 5-amiono salicylic acids (5-ASA), immune modulators, and corticosteroids. However, there is insufficient data about its efficacy and safety in Korea. METHODS From 7 tertiary referral hospitals, 33 patients who were treated with ...

Journal: :Blood 1975
R Willemze H Hillen C A Hartgrink-Groeneveld C Haanen

During the period from January 1970 until December 1973, therapy was started in 41 previously untreated adolescents and adults with acute lymphoblastic leukemia. Induction therapy was started with vincristine and prednisone in all patients, resulting in complete remission in 19 and death due to infection during the first month in one case. After 3 wk on these two drugs, the addition of daunorub...

Journal: :iranian red crescent medical journal 0
shekoufeh nikfar department of pharmacoeconomics and pharmaceutical administration, faculty of pharmacy, tehran university of medical sciences, tehran, ir iran; food and drug organization, ministry of health and medical education, tehran, ir iran solmaz ehteshami-afshar faculty of medicine, shahid beheshti university of medical sciences, tehran, ir iran; faculty of pharmacy, and pharmaceutical sciences research center, tehran university of medical sciences, tehran, ir iran mohammad abdollahi department of pharmacoeconomics and pharmaceutical administration, faculty of pharmacy, tehran university of medical sciences, tehran, ir iran; faculty of pharmacy, and pharmaceutical sciences research center, tehran university of medical sciences, tehran, ir iran; faculty of pharmacy, and pharmaceutical sciences research center, tehran university of medical sciences, tehran, ir iran. tel: +98-2164122319, fax: +98-2166959104

conclusions cp is effective for inducing clinical response and maintenance of clinical remission in patients with moderate to severe cd with similar side-effect profile as the control arms. background tumor necrosis factor-α (tnf-α) antibodies are currently used in patients with moderate to severe crohn’s disease (cd) who are unresponsive to conventional therapies. certolizumab pegol (cp) is on...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید